William Guyer, serving as the Chief Development Officer at Corcept Therapeutics Inc. (NASDAQ:CORT), executed a sale of 20,000 shares of the company’s common stock on June 2, 2026. The transaction resulted in a total value of $1,412,000. The shares were divested at prices ranging from $70.44 to $70.86 per share, establishing a weighted average sale price of $70.60.
The sale was conducted under a Rule 10b5-1 trading plan, which Mr. Guyer originally adopted on November 27, 2024. This pre-arranged framework dictates the timing and execution of the transaction, independent of current market conditions or insider knowledge at the time of the sale.
The timing of this divestiture coincides with a substantial appreciation in Corcept’s share price. The stock has surged over 108% year-to-date as of the transaction date, currently trading at $74.89. This current market price sits above Mr. Guyer’s realized sale price of $70.60. According to InvestingPro analysis, the stock appears fairly valued at its current levels. However, the company is trading at a high earnings multiple, evidenced by a P/E ratio of 186.49. Investors seeking deeper analysis can access 13 additional ProTips and comprehensive Pro Research Reports.
Concurrently with the sale, Mr. Guyer acquired 20,000 shares of common stock through the exercise of stock options on the same day. The exercise price was $21.65 per share, totaling $433,000. These options were fully exercisable at the time of the transaction.
Following these transactions, Mr. Guyer’s direct holdings in Corcept Therapeutics common stock stand at 3,985 shares. This total includes 224 shares, 498 shares, and 877 shares underlying unvested restricted stock awards granted on December 1, 2025, March 2, 2026, and June 2, 2026, respectively. These restricted stock awards are set to vest on their one-year anniversary dates, subject to certain conditions. Additionally, Mr. Guyer holds 150,000 stock options.
In related corporate developments, Corcept Therapeutics reported its first-quarter 2026 earnings, revealing a revenue increase to $164.9 million, marking a 4.9% rise year-over-year. The company experienced a net loss of $31.8 million. Despite this loss, Corcept raised its full-year revenue guidance to between $950 million and $1.05 billion, attributing the increase to the successful launch of Lifyorli. Additionally, Corcept presented encouraging overall survival data from its Phase 3 ROSELLA trial at the ASCO 2026 Annual Meeting. The trial demonstrated a 35% reduction in the risk of death for patients receiving Lifyorli combined with nab-paclitaxel compared to nab-paclitaxel alone.
In a related regulatory development, Corcept announced plans to resubmit its New Drug Application to the FDA for relacorilant as a treatment for Cushing’s syndrome. The FDA had requested additional analyses following a complete response letter. Meanwhile, H.C. Wainwright raised its price target for Corcept shares to $75 from $65, maintaining a Buy rating due to the company’s revenue guidance.
Corcept Therapeutics Incorporated Follow Analyze CORT Included in our AI-picked strategies Review strategies 74.89 ▲+2.24(+3.08%) Closed 74.89 0.00(0.00%) After Hours · 16:10:04 1D 1W 1M 6M 1Y 5Y Max Analyze CORT This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. See the trade on CORT, but can't pull the trigger? Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time. Try Chart Analysis for CORT